Drug Database
TE

teriparatide (Xinfutai)

✓ Approved

Shenzhen Salubris Pharmaceuticals Co., Ltd. · PTH1R · Recombinant Proteins

What is teriparatide?

teriparatide is a recombinant proteins developed by Shenzhen Salubris Pharmaceuticals Co., Ltd.. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand NamesXinfutai
CompanyShenzhen Salubris Pharmaceuticals Co., Ltd.
Drug ClassRecombinant Proteins
Molecular TargetPTH1R
RouteInjectable (Others), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Shenzhen Salubris Pharmaceuticals Co., Ltd.

Mechanism of Action

Molecular Targets

teriparatide acts on 1 molecular target:

PTH1Rparathyroid hormone 1 receptor (PTHR, EKNS)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

teriparatide is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Musculoskeletal and connective tissue disordersOsteoporosis✓ Approved

Related Research Articles

PubMedClinics in orthopedic surgery2026-10-15

Conservative Treatment with Adjunctive Use of Teriparatide for Periprosthetic Humeral Fractures after Reverse Total Shoulder Arthroplasty: A Report of 6 Cases.

Sohn Hyuk-Joon HJ, Park Bum-Soon BS, Hwang Junkyung J, Yoon Jong Pil JP et al.

Periprosthetic humeral fractures (PPHFs) after reverse total shoulder arthroplasty (RTSA) are challenging complications, particularly in elderly patients with osteoporotic bone and multiple comorbidities. Although surgical treatment is commonly recommended for displaced fractures, conservative management may be preferable in high-risk patients. This study reports 6 cases of PPHF after RTSA successfully treated with conservative management incorporating adjunctive teriparatide therapy. Six patients (mean age, 77.2 years; range, 70-87 years) who developed PPHF after RTSA were treated nonoperatively with daily subcutaneous teriparatide (20 µg) and immobilization using an abduction brace. The mean follow-up duration was 23.8 months (range, 12-36 months). Fractures were classified according to the Wright and Cofield classification system. Radiographic outcomes were assessed using serial plain radiographs. Clinical outcomes were evaluated using the visual analog scale (VAS) pain score, American Shoulder and Elbow Surgeons (ASES) score, and active range of motion. Fracture patterns included type A (n = 1), type B (n = 4), and type C (n = 1). Radiographic union was achieved in all patients (100%) at a mean of 2.7 months (range, 2-4 months). One patient developed malunion. At final follow-up, the mean VAS pain score was 2.2 and the mean ASES score was 69.8. No teriparatide-related adverse events were observed. Conservative management with adjunctive teriparatide therapy resulted in reliable radiographic union of PPHF following RTSA in selected patients. In addition to fracture classification, factors such as fracture displacement, angular deformity, implant stability, and patient-specific clinical characteristics should be carefully considered when determining treatment strategy. This approach may represent a viable alternative for elderly patients with substantial medical comorbidities in whom surgical treatment carries considerable risk.

PMID 42876896
Read full article →
PubMedBMC pharmacology & toxicology2026-10-15

Development and validation of a GC-MS method for the determination of ethylene glycol and diethylene glycol in pharmaceutical syrups.

Amil Muhammad Amirul MA, Mohamad Adzib Muhammad Shahariz MS, Bujang Nur Baizura NB, Gan Kok Zheng KZ et al.

Contamination of pharmaceutical syrups with ethylene glycol (EG) and diethylene glycol (DEG) has led to serious poisoning incidents worldwide, highlighting the necessity for strong regulations and reliable testing methods. A gas chromatography-mass spectrometry (GC-MS) method was developed and validated in accordance with ICH Q2(R2) guidelines. The method was developed for pharmaceutical syrup matrices and validated using multiple commercially available products, supporting its applicability for routine regulatory surveillance. It exhibited excellent linearity, with r² of 0.9991 for EG and 0.9963 for DEG. The detection (LOD) and quantification (LOQ) limits were 0.02% v/v and 0.06% v/v, respectively, below the regulatory limit of 0.10% set by the National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia. Accuracy ranged from 94.2% to 108.4%, and the %RSD for intermediate precision was 1.4% for EG and 2.5% for DEG, confirming the method's reproducibility. When the validated method was applied to 51 pharmaceutical syrup samples available in the Malaysian market as part of post-market surveillance, 13 samples were detected to have EG. Of these, 11 samples had EG concentrations between the LOD and the LOQ, while two samples (PS-13 and PS-26) had measurable levels at 0.09% v/v. DEG was not detected in any sample. Therefore, this study emphasises the importance of regulatory surveillance, supported by validated analytical testing, to ensure the quality and safety of pharmaceutical syrups. Strengthening local surveillance mechanisms will further strengthen NPRA's regulatory capacity and safeguard public health.

PMID 42875787
Read full article →
PubMedThe British journal of sociology2026-10-15

Temporal Structuration: Negotiating Reproductive Timing in Urban China.

You Xijia X

This article develops the concept of temporal structuration to explain how actors engage temporal norms as social structures. Based on 64 life story interviews in Shenzhen and analysed through constructivist grounded theory, it examines reproductive timing in urban China, where marriage and childbearing are organised by a dense timetable enforced through kin relations. The analysis identifies a situated repertoire of four types of strategy: accommodation, transformation, redirection and identity-based claims, which participants combined and redeployed as relationships, pressures and available resources changed. The strategies act upon the norm's enforcement, justification, operating conditions and applicability, respectively, while drawing on the categories and relationships that sustain it. Postponement thus emerges as a relational accomplishment, maintained through practical, justificatory, identity and emotion work. Temporal structuration thus captures the recursive process through which actors secure room for alternative timing while reproducing-and potentially, through collective accumulation, altering-the norm's authority and operation. This article therefore extends the temporal dimension of structure and agency, advances the empirical understanding of temporal agency, and enriches the processual understanding of temporal experience.

PMID 42876014
Read full article →
PubMedFrontiers in medicine2026-10-15

Case Report: Analysis of antimicrobial therapy and pharmaceutical care of mixed Aspergillus and Mycobacterium tuberculosis infection following renal transplantation: a case study.

Zhang Jiao J, Zhao Yue Y, Peng Yang Y, Zheng Xin X

Invasive infection is a significant complication following renal transplantation. Due to long-term immunosuppressive therapy, renal transplant recipients are at high risk for fungal infections and tuberculosis, which are also major causes of mortality in this population. Triazole drugs, as first-line agents for invasive fungal infections, can cause fluctuations in the blood levels of immunosuppressants due to drug-drug interactions. Furthermore, the concomitant use of antituberculosis drugs further complicates the balance between maintaining immunosuppression and anti-infective therapy, often presenting a challenge to clinical decision-making. This article discusses the role of the clinical pharmacist in the treatment of a renal transplant recipient who developed concurrent pulmonary tuberculosis and aspergillus infection. By recommending initial regimens, adjusting doses during outpatient follow-ups, and assessing adverse drug reactions, the clinical pharmacist provided systematic pharmaceutical services. This collaboration assisted physicians in developing a personalized treatment plan, ultimately achieving favorable therapeutic outcomes for the patient.

PMID 42876480
Read full article →
PubMedDrugs2026-10-15

Ciprocopan: First Approval.

Fung Simon S

Ciprocopan (®) is a small molecule inhibitor of complement factor B, which is a key component of the alternative complement pathway. It is being developed by Haisco Pharmaceutical Group for the treatment of complement-mediated disorders. In July 2026, ciprocopan received its first approval for treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have not previously received treatment with a complement inhibitor therapy in China. This article summarizes the milestones in the development of ciprocopan leading to this first approval.

PMID 42875656
Read full article →
PubMedJournal of Alzheimer's disease reports2026-10-15

Machine learning-based screening for Ascertain Dementia 8-defined suspected cognitive impairment leveraging routine health check data in South China.

Su Peiyue P, Li Jiale J, Hu Yang Y, Xu Yue Y et al.

Timely detection of cognitive concerns can facilitate further assessment, referral, and management; however, cognitive impairment often remains under-detected in primary care settings, representing a missed opportunity for early detection for Alzheimer's disease and related dementias. We aimed to develop and internally validate a machine learning-based cross-sectional concurrent classification model that utilizes routine health check data only, supporting concurrent identification of individuals with Ascertain Dementia 8 (AD8)-defined suspected cognitive impairment who warrant further clinical cognitive evaluation. This cross-sectional study included 7440 adults (aged ≥65 years) from the 2021 Elderly Health Check Program in Shenzhen, China. Suspected cognitive impairment was defined as an AD8 score ≥2. Following data splitting, feature selection was processed via the Boruta algorithm. Five algorithms-logistic regression, random forest, XGBoost, SVM, and EasyEnsemble-were evaluated. Performance was assessed using ROC, PR, accuracy, sensitivity, specificity, PPV, NPV, NNS, DCA, calibration plots, and Brier score. The EasyEnsemble model outperformed other algorithms on the independent testing set, with an ROC-AUC of 0.696 (Bootstrap-corrected mean: 0.677; 95% CI: 0.643-0.713). At the clinically optimized threshold of 0.034, the model achieved a sensitivity of 60.6%, a specificity of 73.4% and a NNS of 51.9. DCA indicated a positive net benefit across a threshold range approximately from 0.03 to 0.20, suggesting potential clinical utility for triage in this setting. This cross-sectional model provides a pragmatic, low-cost tool for concurrent case-finding of individuals with AD8-defined suspected cognitive impairment in primary care. However, further external validation in diverse geographic regions is mandatory before clinical implementation.

PMID 42876944
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about teriparatide